Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387348 · ClinicalTrials.gov registry record · Phase 3
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT00387348: Clinical Trial Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00387348 is a Phase 3 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387348, a Phase 3 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer. It is not yet known whether escitalopram is more effective than a placebo in treating depression in patients with advanced lung or gastrointestinal cancer. PURPOSE: This randomized clinical trial is studying the side effects of escitalopram and to see how well it works compared to a placebo in treating depression in patients with advanced lung or gastrointestinal cancer.
Interventions
- DRUG Placebo
- DRUG escitalopram oxalate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387348
The ClinicalTrials.gov registry entry for NCT00387348 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00387348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387348 about?
NCT00387348 is a clinical study titled "Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer". RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer. It is not yet known whether escitalopram is more effective than a placebo in treating depression in patients with advanced lung or gastrointestinal cancer. PURPOSE: Thi...
What is the current status of trial NCT00387348?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2006-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00387348?
The interventions under investigation include: Placebo (DRUG), escitalopram oxalate (DRUG).
Who is sponsoring clinical trial NCT00387348?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.